Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Equities researchers at Leerink Partnrs raised their FY2023 EPS estimates for shares of Monte Rosa Therapeutics in a note issued to investors on Tuesday, October 17th. Leerink Partnrs analyst C. Liu now forecasts that the company will earn ($1.75) per share for the year, up from […]
Related Keywords
Leerink Partnrs , Nasdaq , Credit Suisse Group , Vanguard Group Inc , Blackrock Inc , Monte Rosa Therapeutics Inc , Citadel Advisors , Jpmorgan Chase Co , Monte Rosa Therapeutics , Free Report , Monte Rosa Therapeutic , Rosa Therapeutics , Get Free Report , Suisse Group , Point Capital Management , Monte Rosa Therapeutics Daily , Nasdaq Glue , Glue , Medical , Earnings Estimates ,
vimarsana.com © 2020. All Rights Reserved.